Condition

Metastatic Castration-Resistant Prostate Carcinoma

ClinicalTrials.gov condition label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 9 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials9
Recruiting4
Common interventions25
Lead sponsors shown5
Advertisement

Clinical trials

9 shown
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL TrialNCT07200830 · 2026-03-31
RECRUITING
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing DiseaseNCT06526299 · 2025-04-29
RECRUITING
SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) TherapyNCT07096999 · 2025-01-23
RECRUITING
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate CancerNCT06236139 · 2024-11-26
RECRUITING
Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate CancerNCT07682649 · 2026-08-01
NOT_YET_RECRUITING
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP StudyNCT05960578 · 2024-05-23
ACTIVE_NOT_RECRUITING
Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate CancerNCT05828082 · 2023-10-16
ACTIVE_NOT_RECRUITING
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate CancerNCT04777071 · 2021-05-17
ACTIVE_NOT_RECRUITING
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal TherapyNCT04071236 · 2020-10-14
ACTIVE_NOT_RECRUITING

Common interventions

Trial status mix

ACTIVE_NOT_RECRUITING4
RECRUITING4
NOT_YET_RECRUITING1

Phase mix

PHASE26
PHASE13
PHASE31
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.